AUS
NZ
UK
CA
USA
IND
Highlights
- ResMed shares surged 40.8% in 2024, highlighting its strong position in the medical equipment sector.
- Netwealth Group is trading 104.5% above its 52-week low, reflecting a robust recovery in wealth management.
- ResMed’s price-to-sales ratio of 5.17x indicates potential growth, trading below its five-year average.
The share price of ResMed CDI has experienced a remarkable rise of 40.8% since the beginning of 2024, highlighting the company’s strong position in the medical equipment sector. In contrast, Netwealth Group Ltd is currently trading approximately 104.5% above its 52-week low, reflecting its recovery in the wealth management space.
ResMed (ASX:RMD)
Founded in 1989 by Peter Farrell, ResMed is an Australian medical equipment company now headquartered in San Diego, California. Specializing in cloud-connected continuous positive airway pressure (CPAP) machines, ResMed plays a crucial role in the treatment of obstructive sleep apnea (OSA). While the company has its primary listing on the NYSE, it is also publicly traded on the ASX.
ResMed operates on a global scale with a workforce of over 10,000 employees and a presence in more than 140 countries. The company is divided into two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS).
- Sleep and Respiratory Care: This unit offers leading CPAP machines designed for individuals suffering from sleep apnea. Additionally, it caters to patients who require various levels of respiratory support, from non-invasive ventilation to life-support solutions.
- Software as a Service (SaaS): ResMed's SaaS division develops software that aids in the management of durable and home medical equipment (DME/HME), facilitating out-of-hospital care.
Thanks to its expansive digital health network, powered by cloud-connected devices, ResMed is able to leverage industry-leading hardware, such as masks and humidifiers. This integration of technology and data allows ResMed to drive valuable insights, enhance patient outcomes, and reduce overall healthcare costs.
Netwealth Group (ASX:NWL)
Founded in 1999, Netwealth Group Ltd operates a wealth management platform designed for financial planners to effectively manage client investments. As of 2024, Netwealth has attracted over 140,000 account holders and oversees more than $88 billion in funds under administration (FUA).
Netwealth’s strength lies in its scalability and user-friendly interface, which provides a seamless experience for users. Through a single online dashboard, clients can manage their investments, track performance, and access charts, reports, and tax statements—all in one place.
Valuation Insights for ResMed CDI
As a growth-oriented company, evaluating the potential of ResMed's share price involves comparing its price-to-sales (P/S) multiple over time. Currently, ResMed's shares exhibit a price-to-sales ratio of 5.17x, which is below its five-year average of 6.13x. This suggests that ResMed shares are trading below their historical average, indicating a potential opportunity for growth. However, it is essential to consider multiple valuation metrics and context when making investment assessments.
Both ResMed CDI and Netwealth Group Ltd demonstrate robust performance in their respective sectors. ResMed continues to lead in innovative medical solutions for sleep and respiratory care, while Netwealth provides a comprehensive platform for wealth management. As market conditions evolve, monitoring these companies' performances and growth prospects will be crucial for stakeholders.
